TW201613579A - Pharmaceutical composition for oral administration - Google Patents
Pharmaceutical composition for oral administrationInfo
- Publication number
- TW201613579A TW201613579A TW104120176A TW104120176A TW201613579A TW 201613579 A TW201613579 A TW 201613579A TW 104120176 A TW104120176 A TW 104120176A TW 104120176 A TW104120176 A TW 104120176A TW 201613579 A TW201613579 A TW 201613579A
- Authority
- TW
- Taiwan
- Prior art keywords
- pharmaceutical composition
- oral administration
- compound
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 229940126062 Compound A Drugs 0.000 abstract 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 229920000642 polymer Polymers 0.000 abstract 1
- 238000005549 size reduction Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014129374 | 2014-06-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW201613579A true TW201613579A (en) | 2016-04-16 |
Family
ID=54938194
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW104120176A TW201613579A (en) | 2014-06-24 | 2015-06-23 | Pharmaceutical composition for oral administration |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9775832B2 (zh) |
| EP (1) | EP3162368A4 (zh) |
| JP (1) | JPWO2015199115A1 (zh) |
| CN (1) | CN106456612A (zh) |
| HK (1) | HK1232144A1 (zh) |
| MX (1) | MX362193B (zh) |
| PH (1) | PH12016502285A1 (zh) |
| TW (1) | TW201613579A (zh) |
| WO (1) | WO2015199115A1 (zh) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3318259B1 (en) | 2015-07-03 | 2023-01-11 | Astellas Pharma Inc. | Stable pharmaceutical composition for oral administration |
| MX2020001877A (es) * | 2017-08-18 | 2020-09-14 | Abbvie Inc | Formulaciones farmacéuticas para tratar la endometriosis, los fibromas uterinos, el síndrome de ovario poliquístico o la adenomiosis. |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5948810B2 (ja) | 1980-03-22 | 1984-11-29 | 山之内製薬株式会社 | ニカルジピン持続性製剤用組成物 |
| CA1146866A (en) | 1979-07-05 | 1983-05-24 | Yamanouchi Pharmaceutical Co. Ltd. | Process for the production of sustained release pharmaceutical composition of solid medical material |
| TW486370B (en) | 1996-12-25 | 2002-05-11 | Yamanouchi Pharma Co Ltd | Rapidly disintegrable pharmaceutical composition |
| CZ20022047A3 (cs) | 1999-12-23 | 2003-09-17 | Pfizer Products Inc. | Farmaceutické kompozice poskytující zvýšenou koncentraci léčiva |
| EP1864976B1 (en) * | 2005-03-31 | 2012-10-10 | Astellas Pharma Inc. | Propane-1,3-dion derivative or salt thereof |
| JP5517327B2 (ja) * | 2008-12-16 | 2014-06-11 | 日医工株式会社 | 口腔内崩壊錠用組成物 |
| JP6063379B2 (ja) * | 2011-04-22 | 2017-01-18 | アステラス製薬株式会社 | 固形医薬組成物 |
| JP2013180961A (ja) * | 2012-02-29 | 2013-09-12 | Astellas Pharma Inc | Ws727713含有固形製剤 |
| JP2014051470A (ja) * | 2012-09-07 | 2014-03-20 | Astellas Pharma Inc | スルホニルアミジン化合物の結晶 |
| CA2883126A1 (en) | 2012-09-07 | 2014-03-13 | Astellas Pharma Inc. | Method for producing sulfonyl amidine compound |
-
2015
- 2015-06-23 TW TW104120176A patent/TW201613579A/zh unknown
- 2015-06-24 WO PCT/JP2015/068139 patent/WO2015199115A1/ja not_active Ceased
- 2015-06-24 US US15/319,355 patent/US9775832B2/en not_active Expired - Fee Related
- 2015-06-24 HK HK17105851.8A patent/HK1232144A1/zh unknown
- 2015-06-24 EP EP15812265.5A patent/EP3162368A4/en not_active Withdrawn
- 2015-06-24 CN CN201580034384.1A patent/CN106456612A/zh not_active Withdrawn
- 2015-06-24 MX MX2016017402A patent/MX362193B/es active IP Right Grant
- 2015-06-24 JP JP2016529621A patent/JPWO2015199115A1/ja active Pending
-
2016
- 2016-11-16 PH PH12016502285A patent/PH12016502285A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN106456612A (zh) | 2017-02-22 |
| EP3162368A1 (en) | 2017-05-03 |
| US9775832B2 (en) | 2017-10-03 |
| MX362193B (es) | 2019-01-08 |
| EP3162368A4 (en) | 2018-03-07 |
| US20170143678A1 (en) | 2017-05-25 |
| HK1232144A1 (zh) | 2018-01-05 |
| PH12016502285A1 (en) | 2017-02-13 |
| MX2016017402A (es) | 2017-05-01 |
| JPWO2015199115A1 (ja) | 2017-04-20 |
| WO2015199115A1 (ja) | 2015-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021014509A (es) | Composiciones farmaceuticas que comprenden meloxicam. | |
| MY199007A (en) | Pharmaceutical compositions comprising meloxicam | |
| CR20200064A (es) | Carboxamidas como moduladores de los canales de sodio | |
| PH12016501310A1 (en) | Pharmaceutical compositions comprising azd9291 | |
| EP4467600A3 (en) | Pharmaceutical compositions comprising meloxicam | |
| NZ734233A (en) | Pharmaceutical compositions comprising meloxicam | |
| MX2016006053A (es) | Compuestos selectivos de peptido yy (pyy) y usos de los mismos. | |
| PH12016500170A1 (en) | Formulation of syk inhibitors | |
| MX394588B (es) | Composición farmacéutica. | |
| CL2017001479A1 (es) | Combinación farmacéutica que comprende un agonista selectivo del receptor s1p1 | |
| EA201201202A1 (ru) | Пероральная фармацевтическая композиция, содержащая этексилат дабигатрана | |
| MX2016011105A (es) | Inhibidores de monoacilglicerol aciltransferasa 2 (mgat2) de dihidropiridinona para usarse en el tratamiento de trastornos metabolicos. | |
| EP4275707A3 (en) | Formulations of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide | |
| PH12017502252A1 (en) | Stable pharmaceutical composition for oral administration | |
| EA201692298A1 (ru) | Производные карбоксамидов | |
| MX2017013896A (es) | Composicion farmaceutica para administracion oral. | |
| PH12016502285A1 (en) | Pharmaceutical composition for oral administration | |
| MY175971A (en) | Heterocyclic acetamide compound | |
| PH12016502527B1 (en) | Stabilized desmopressin | |
| NZ731220A (en) | Methods for treating kidney disorders | |
| TH167761A (th) | องค์ประกอบทางเภสัชกรรมสำหรับให้ทางปาก | |
| UA113436U (xx) | Лікарський засіб для лікування ішемічних уражень тканин | |
| MY203481A (en) | Pharmaceutical compositions comprising meloxicam | |
| UA91650U (uk) | Фармацевтична композиція похідних гамма-аміномасляної кислоти для твердих капсул |